Evolus Says Launch of Its Botox Rival Ahead of Its Expectations Evolus Says Launch of Its Botox Rival Ahead of Its Expectations
Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.Reuters Health Information
Publication date: September 2020Source: Molecular Immunology, Volume 125Author(s): Saburo Saito, Hidenori Takagi, Yuhya Wakasa, Kenjirou Ozawa, Fumio Takaiwa
Condition: Food Allergy Intervention: Sponsor: UMC Utrecht Recruiting
Incorporating skin toxicity protocols at a cancer center significantly increased the rate of prophylactic treatment for rashes resulting from cancer therapies.Medscape Medical News
WEDNESDAY, July 8, 2020 -- Penicillin allergy is often unconfirmed in hospital patients, meaning many unnecessarily receive other antibiotics that may be less effective and even harmful, a new study finds. The researchers analyzed records of nearly...
Is there a possible link between COPD, lung function, and the risk for developing type 2 diabetes?BMC Pulmonary Medicine
Clinicians often prescribe a short course of oral steroids for self-limiting conditions, but a growing body of data suggests such treatments are tied to severe adverse events.Medscape Medical News
(American College of Allergy, Asthma, and Immunology) Due to COVID-19, the 2020 ACAAI Annual Scientific Meeting will be held remotely.
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has established a new clinical trials network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.
(University of South Carolina) UofSC researchers from its Big Data Health Science Center initiative have received $1.25 million in grant funding from the NIH National Institute of Allergy and Infectious Diseases (NIAID) to develop a data-driven system to track COVID-19 in South Carolina.
(Fred Hutchinson Cancer Research Center) Fred Hutchinson Cancer Research Center has been named the coordinating center for vaccine clinical trials of the COVID-19 Prevention Network (COVPN), funded by the National Institute of Allergy and Infectious Diseases.